Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,208
  • Shares Outstanding, K 36,239
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,260 K
  • EBIT $ -151 M
  • EBITDA $ -150 M
  • 60-Month Beta -0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 120.26% ( +29.86%)
  • Historical Volatility 75.74%
  • IV Percentile 59%
  • IV Rank 30.46%
  • IV High 290.82% on 12/09/24
  • IV Low 45.55% on 06/06/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 286
  • Volume Avg (30-Day) 200
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 15,411
  • Open Int (30-Day) 15,913

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.00
  • Number of Estimates 5
  • High Estimate -0.86
  • Low Estimate -1.20
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -2.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +0.20%
on 03/10/25
3.96 -36.74%
on 02/18/25
-1.25 (-33.29%)
since 02/10/25
3-Month
2.50 +0.20%
on 03/10/25
6.44 -61.10%
on 12/11/24
-3.26 (-56.51%)
since 12/10/24
52-Week
2.50 +0.20%
on 03/10/25
18.40 -86.39%
on 03/15/24
-12.85 (-83.69%)
since 03/08/24

Most Recent Stories

More News
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BMEA : 2.51 (-7.56%)
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

BMEA : 2.51 (-7.56%)
Biomea Fusion to Become a Diabetes & Obesity Medicines Company

BMEA : 2.51 (-7.56%)
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

BMEA : 2.51 (-7.56%)
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BMEA : 2.51 (-7.56%)
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

BMEA : 2.51 (-7.56%)
Biomea Fusion to Host Conference Call Presenting Topline Results from Phase II Trial of Icovamenib in Type 2 Diabetes

Biomea Fusion will discuss COVALENT-111 Phase II trial results for icovamenib in type 2 diabetes on December 17, 2024.Quiver AI SummaryBiomea Fusion, Inc. announced that it will host a conference call...

BMEA : 2.51 (-7.56%)
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

BMEA : 2.51 (-7.56%)
Biomea Fusion Announces Promising Preclinical Results for Icovamenib in Enhancing Beta Cell Function and Synergy with GLP-1-Based Therapies

Icovamenib improves beta cell function and insulin secretion, enhancing effectiveness of GLP-1 therapies in diabetes treatment.Quiver AI SummaryBiomea Fusion, Inc. announced positive results from preclinical...

BMEA : 2.51 (-7.56%)
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

BMEA : 2.51 (-7.56%)

Business Summary

Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion Inc. is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 2.94
2nd Resistance Point 2.85
1st Resistance Point 2.68
Last Price 2.51
1st Support Level 2.42
2nd Support Level 2.33
3rd Support Level 2.16

See More

52-Week High 18.40
Fibonacci 61.8% 12.33
Fibonacci 50% 10.45
Fibonacci 38.2% 8.57
Last Price 2.51
52-Week Low 2.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar